PFE FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
Story updates
08:31:08 PM UTC
SquawkNews
PFE FDA grants priority review for pfizer’s talzenna plus xtandi for the treatment of metastatic prostate cancer Pfizer - FDA sets pdufa action date for talzenna plus xtandi in Q4 2026
08:35:59 PM UTC
SquawkNews
PFE - FDA Grants Priority Review for Pfizer’s TALZENNA Plus XTANDI for the Treatment of Metastatic Prostate Cancer
08:39:47 PM UTC
SquawkNews
Pfizer announced that the...
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.